Q32 Bio to Participate in Upcoming September Investor Conferences
Rhea-AI Summary
Q32 Bio Inc. (Nasdaq: QTTB), a clinical stage biotechnology company, has announced its participation in three upcoming investor conferences in September 2024. The company, which focuses on developing biologic therapeutics to restore immune homeostasis, will be present at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 in New York, NY
2. 2024 Cantor Fitzgerald Global Healthcare Conference on September 17 in New York, NY (presentation at 3:40 p.m. E.T.)
3. Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 (virtual presentation at 11:30 a.m. E.T.)
Webcasts of the Cantor and Stifel presentations will be available on Q32 Bio's website, with archived replays accessible for 30 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction – QTTB
In the trading session that priced this news, QTTB gained 1.58%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Thursday, September 5, 2024
Location:
2024 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, September 17, 2024
Presentation Time: 3:40 p.m. E.T.
Location:
Stifel 2024 Virtual Immunology and Inflammation Summit
Date: Wednesday, September 18, 2024
Presentation Time: 11:30 a.m. E.T.
Location: Virtual
A webcast of the Cantor and Stifel presentations will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 30 days following the event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives.
Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase 2 trials for the treatment of atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has completed a first-in-human, Phase 1 ascending dose clinical study of ADX-097 in healthy volunteers.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Contacts:
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-upcoming-september-investor-conferences-302233260.html
SOURCE Q32 Bio